LIDDS employs Head of Business Development
LIDDS announces today that Markus Thor has been appointed as Head of Business Development and will join the company in March 2019. The employment is a consequence of the enlarged project portfolio and the broad interest from the pharma industry for the NanoZolid technology.
Markus Thor has a thorough experience in business development and out-licensing from companies like Biovitrum, Kancera and Medivir. Markus holds an Executive MBA from Stockholm School of Economics and MSc in Chemistry from University of Umeå.
-We are very happy to welcome Markus to LIDDS. He has a solid background and substantial deal track record and will be a good asset in our management team. Markus will have an important role in the company's expansive phase as the NanoZolid® technology opens up many business opportunities, says Monica Wallter, CEO of LIDDS.
-I am excited to join the competent LIDDS team and look forward to contributing in the company's further development and value creation, says Markus Thor.
Markus currently works as Senior Investment Advisor at Business Sweden and will start his new position at LIDDS in March 2019.
For more information, please contact:
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, firstname.lastname@example.org
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North (LIDDS). Redeye AB is the Certified Adviser to LIDDS (+46 (0) 8 121 576 90, email: email@example.com). For more information, please visit www.liddspharma.com.
Upcoming Life Sciences Events
- September 2019
- Boston: 9th Annual American Drug Delivery & Formulation Summit
- Malmo: NLS Days 2019
- Boston: Redefining Early Stage Investments (RESI)
Latest company news
There are currently no news available for this portal